SNCA and Parkinson disease: Nevertheless, although we experimentally demonstrated that LETX-VI can downregulate the expression of α-synuclein and improve the behaviors of Parkinson’s disease, thus having potential application prospects for the prevention and treatment of PD, the relevant mechanism of action of LETX-VI is not completely clear and needs further investigation in the future work.